genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2024
Ultragenyx Pharmaceutical
Bioprocessing
Intellia and Ultragenyx’s Clinical Updates, Novo Holdings’ Catalent Acquisition, and NanoString Bankruptcy; Simon Barnett
Drug Discovery
Ultragenyx’s Gene Therapy Ameliorates Pediatric Neurodegenerative Disorder
Bioprocessing
BPI News: Cell Line Development’s Critical Role in Gene Therapy
Bioprocessing
Ultragenyx Opens New Gene Therapy Manufacturing Facility
Genome Editing
Live from Los Angeles, ASGCT Goes Prime Time
Bioprocessing
Overcoming Scale-Up Challenges in Gene Therapy Manufacturing
Genome Editing
Dimension Therapeutics Spurns Regenxbio for Sweeter Ultragenyx Offer
Genome Editing
Ultragenyx Offers $138M for Dimension Therapeutics, as Bidding War with Regenxbio Looms
Industry News
Takeda to Invest $65M in Ultragenyx under Rare Disease Drug Collaboration
Industry News
Ultragenyx, Arcturus Launch Up-to-$1.56B+ Rare Disease Collaboration
1
2
Page 1 of 2
Scroll Up